Feng Pan1,2, Ling-Li Zhang3, Hong-Jun Luo4, Ye Chen1,5, Lin Long1,2, Xuan Wang1,2, Pei-Tong Zhuang1,2, En-Min Li6,7, Li-Yan Xu8,9. 1. Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China. 2. Department of Biochemistry and Molecular Biology, Shantou University Medical College, No.22, Xinling Road, Shantou, 515041, Guangdong, China. 3. Department of Experimental Animal Center, Shantou University Medical College, Shantou, 515041, China. 4. Bioanalytical Laboratory, Shantou University Medical College, Shantou, 515041, China. 5. Institute of Oncologic Pathology, Shantou University Medical College, No.22, Xinling Road, Shantou, 515041, Guangdong, China. 6. Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China. nmli@stu.edu.cn. 7. Department of Biochemistry and Molecular Biology, Shantou University Medical College, No.22, Xinling Road, Shantou, 515041, Guangdong, China. nmli@stu.edu.cn. 8. Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China. lyxu@stu.edu.cn. 9. Institute of Oncologic Pathology, Shantou University Medical College, No.22, Xinling Road, Shantou, 515041, Guangdong, China. lyxu@stu.edu.cn.
Abstract
PURPOSE: Riboflavin deficiency causes ariboflavinosis, a common nutritional deficiency disease. The purpose of this study is to investigate the effects of riboflavin deficiency on the important internal organs and its potential mechanisms. METHODS: Experiment 1, male F344 rats were randomly assigned to R6 (normal riboflavin, 6 mg/kg) and R0 (riboflavin-deficient, 0 mg/kg) groups. Experiment 2 rats were assigned to R6, R0.6 (0.6 mg/kg) and R0.06 (0.06 mg/kg) groups. Experiment 3 rats were assigned to R6 and R0 → R6 (riboflavin replenishment) groups. Bacterial communities were analyzed based on 16S rRNA gene sequencing. RESULTS: Riboflavin deficiency induced ariboflavinosis (R0.06 46.7%; R0 72%) and esophageal epithelial atrophy (R0.06 40%; R0 44%) in rats, while the R6 group did not display symptoms (P < 0.001, respectively). Esophageal epithelial atrophy occurred simultaneously (R0.06 66.7%; R0 63.6%) with ariboflavinosis or appeared alone (R0.06 33.3%; R0 36.4%). Esophagus is the most vulnerable internal organ. Riboflavin deficiency followed by replenishment (R0 → R6) was effective in treating ariboflavinosis (83.3% vs. 0%, P < 0.001) and esophageal epithelial atrophy (66.7% vs. 20%, P = 0.17). Riboflavin deficiency modulated gut microbiota composition. The several key genera (Romboutsia, Turicibacter and Clostridium sensu stricto 1) were strongly correlated with ariboflavinosis and esophageal epithelial atrophy (P < 0.01 or P < 0.05). The potential mechanism is that gut microbiota affects body's xenobiotic biodegradation and metabolism, and genomic instability. CONCLUSIONS: Riboflavin deficiency induces ariboflavinosis and esophageal epithelial atrophy by modulating the gut microbiota, and offers new Queryinsight into riboflavin deficiency and esophageal lesions.
PURPOSE:Riboflavin deficiency causes ariboflavinosis, a common nutritional deficiency disease. The purpose of this study is to investigate the effects of riboflavin deficiency on the important internal organs and its potential mechanisms. METHODS: Experiment 1, male F344 rats were randomly assigned to R6 (normal riboflavin, 6 mg/kg) and R0 (riboflavin-deficient, 0 mg/kg) groups. Experiment 2 rats were assigned to R6, R0.6 (0.6 mg/kg) and R0.06 (0.06 mg/kg) groups. Experiment 3 rats were assigned to R6 and R0 → R6 (riboflavin replenishment) groups. Bacterial communities were analyzed based on 16S rRNA gene sequencing. RESULTS:Riboflavindeficiency induced ariboflavinosis (R0.06 46.7%; R0 72%) and esophageal epithelial atrophy (R0.06 40%; R0 44%) in rats, while the R6 group did not display symptoms (P < 0.001, respectively). Esophageal epithelial atrophy occurred simultaneously (R0.06 66.7%; R0 63.6%) with ariboflavinosis or appeared alone (R0.06 33.3%; R0 36.4%). Esophagus is the most vulnerable internal organ. Riboflavin deficiency followed by replenishment (R0 → R6) was effective in treating ariboflavinosis (83.3% vs. 0%, P < 0.001) and esophageal epithelial atrophy (66.7% vs. 20%, P = 0.17). Riboflavin deficiency modulated gut microbiota composition. The several key genera (Romboutsia, Turicibacter and Clostridium sensu stricto 1) were strongly correlated with ariboflavinosis and esophageal epithelial atrophy (P < 0.01 or P < 0.05). The potential mechanism is that gut microbiota affects body's xenobiotic biodegradation and metabolism, and genomic instability. CONCLUSIONS:Riboflavin deficiency induces ariboflavinosis and esophageal epithelial atrophy by modulating the gut microbiota, and offers new Queryinsight into riboflavin deficiency and esophageal lesions.
Authors: Kyly C Whitfield; Crystal D Karakochuk; Yazheng Liu; Adrian McCann; Aminuzzaman Talukder; Hou Kroeun; Mary Ward; Helene McNulty; Larry D Lynd; David D Kitts; Eunice C Y Li-Chan; Judy McLean; Timothy J Green Journal: J Nutr Date: 2015-01-07 Impact factor: 4.798
Authors: Hilary J Powers; Marilyn H Hill; Sohail Mushtaq; Jack R Dainty; Gosia Majsak-Newman; Elizabeth A Williams Journal: Am J Clin Nutr Date: 2011-04-27 Impact factor: 7.045
Authors: Jean Guy LeBlanc; Christian Milani; Graciela Savoy de Giori; Fernando Sesma; Douwe van Sinderen; Marco Ventura Journal: Curr Opin Biotechnol Date: 2012-08-30 Impact factor: 9.740
Authors: G B M Mensink; R Fletcher; M Gurinovic; I Huybrechts; L Lafay; L Serra-Majem; L Szponar; I Tetens; J Verkaik-Kloosterman; A Baka; A M Stephen Journal: Br J Nutr Date: 2013-01-14 Impact factor: 3.718